Optimization of antibiotic therapy in the obese, critically ill patient;Optimisation de l’antibiothérapie chez le patient obèse en réanimation

Reanimation

Volumn 24, Issue 3, 2015, Pages 278-294

  Hites, M ^a   Taccone, F S ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Antibiotherapy; Intensive care unit; Obesity; lactams

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MONITORING; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; LIVER CLEARANCE; LIVER FUNCTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; OBESITY;

EID: 84928399468     PISSN: 16240693     EISSN: 19516959     Source Type: Journal    
DOI: 10.1007/s13546-015-1060-8     Document Type: Article

References (123)

1. World Health Organization. Obesity. Available from http://www. who.int/topics/obesity/en/. [Accessed on 15 November, 2014]
2. Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA 307:483–90
3. Marketing of foods high in salt fat and sugar to children. Copenhagen: WHO Regional Office for Europe; 2013.Av_ailable from http://www.euro.who.int/en/health-topics/Life-stages/child-andadolescent- health/publications/2013/marketing- offoods- high-in-fat,-salt-and-sugar-to-children-update-20122013. [Accessed on 25 October, 2014]
4. Ng M, Fleming T, Robinson M, et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet 384:766–81
5. Wang YC, McPherson K, Marsh T, et al (2011) Health and economic burden of the projected obesity trends in the USA and UK. Lancet 378:815–25
6. Falagas ME, Kompoti M (2006) Obesity and infection. Lancet Infect Dis 6:438–46
7. Falagas ME, Athanasoulia AP, Peppas G, Karageorgopoulos DE (2009) Effect of Body mass index on the outcome of infections: a systematic review. Obes Rev 10:280–9
8. Choban PS, Heckler R, Burge JC, Flancbaum L (1995) Increased incidence of nosocomial infections in obese surgical patients. Am Surg 6:1001–5
9. Bertakis KD, Azari R (2005) Obesity and the use of health care services. Obes Res 13:372–9
10. Vincent JL, Rello J, Marshall J, et al (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–9
11. Vazquez-Guillamet C, Scolari M, Zilberberg MD, et al (2014) Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock. Crit Care Med 42:2342–9
12. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–5113.
13. Udy AA, Roberts JA, Lipman J (2013) Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 39:2070–82
14. Hites M, Dell’Anna AM, Scolletta S, et al (2014) The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients. Adv Drug Deliv Rev http://dx.doi.org/10.1016/j.addr.2014.05.007
15. Taccone FS, Laterre PF, Spapen H, et al (2010) Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 14:R53
16. Taccone FS, Laterre PF, Dugernier T, et al (2010) Insufficient ß-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126
17. Beumier M, Roberts JA, Kabtouri H, et al (2013) A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother 68:2859–65
18. Van Zanten ARH, Polderman KH, van Geijlswijk IM, et al (2008) Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 23:422–30
19. Drusano GL (2004) Antibiotic pharmacodynamics: critical interactions of “bug and drug” Nature Reviews 2:289–300
20. Jackson SJ, Leahy FE, McGowan AA, et al (2004) Delayed gastric emptying in the obese: an assessment using the noninvasive (13)C-octanoic acid breath test. Diab Obes Metab 6:679–88
21. Cockshott WP, Thompson GT, Howlett LJ, Seeley ET (1982) Intramuscular or intralipomatous injections? N Engl J Med 307:356–8
22. Genderson K, Shen G (1966) Total body water in obesity. Am J Clin Nutr 19:77–83
23. Forbes GB, Welle SL (1983) Lean body mass in obesity. Int J Obes 7:99–107
24. Benedek IH, Blouin RA, McNamara PJ (1984) Serum protein binding and the role of increased a1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 18:941–6
25. Mavrelis PG, Ammon HV, Gleysteen JJ, et al (1983) Hepatic free fatty acids in alcoholic liver disease and morbid obesity. Hepatology 3:226–31
26. Blouin RA, Kolpek JH, Mann HJ (1997) Influence of obesity on drug disposition. Clin Pharm 6:706–14
27. Morita K, Yamaji A (1995) Changes in the serum protein binding of vancomycin in patients with methicillin resistant Staphylococcus aureus infection: the role of serum a1-acid glycoprotein levels. Ther Drug Monit 17:107–12
28. Suh B, Craig WA, England AC, Elliott RL (1981) Effect of free fatty acids on protein binding of antimicrobial agents. J Infect Dis 149:986–97
29. Summers LK, Samra JS, Humphreys SM, et al (1996) Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity Clin Sci (Lond) 91:679–83
30. Rossi M, Nannipeiri M, Anselmino M, et al (2012) Subcutaneous adipose tissue blood flow and vasomotion in morbidly obese patients: long term effect of gastric bypass surgery. Clin Hemorheol Microcirc 51:159–67
31. Brill MJE, Houwink API, Schmidt J, et al (2014) Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother 69:715–23
32. Hollenstein UM, Brunner M, Schmid R, et al (2001) Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord 25:354–8
33. Joukhader C, Dehghanyar P, Traunmuller F, et al (2005) Increase of microcirculatory blood flow enhances penetration of ciprofloxacin into soft tissue. Antimicrob Agents Chemother 49:4149–53
34. Machado MV, Cortez-Pinto H (2014) Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol 20:12956–80
35. Brill MJ, Diepstraten J, van Rongen A, et al (2012) Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 51:277–304
36. Kotlyar M, Carson SW (1999) Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 37:8–19
37. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI (1983) Enhanced glucoronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 101:873–80
38. Ebert EC (2006) Hypoxic liver injury. Mayo Clin Proc 81:1232–36
39. Hiramatsu A, Takahashi S, Aikata T, et al (2008) Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center. J Gastroenterol Hepatol 23:1216–22
40. Büdingen FV, Gonzalez D, Tucker AN, et al (2014) Relevance of liver failure for anti-infective agents: from pharmacokinetic alterations to dosage adjustments. Ther Adv Infect Dis 2:17–42
41. Barth J, Jäger D, Mundkowski R, et al (2008) Single- and multiple-dose of pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment. J Antimicrob Chemother 62:575–8
42. Montay G, Gaillot J (1990) Pharmacokinetics of fluoroquinolones in hepatic failure. J Antimicrob Chemother 26S:61–7
43. Naora K, Ichikawa N, Hirano H, Iwamoto K (1999) Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure. J Pharm Pharmacol 51:609–16
44. Bosma RJ, Krikken JA, Hman van der Heide JJ, et al (2006) Obesity and renal hemodynamics. Contrib Nephrol 151:184–202
45. Udy AA, Roberts JA, Boots RJ, et al (2010) Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 49:1–16
46. Claus BO, Hoste EA, Colpaert K, et al (2013) Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care 28:695–700
47. Hites M, Taccone FS, Wolff F, et al (2014) Broad-spectrum ß-lactams in obese non-critically ill patients. Nutr Diabetes 4:e119
48. Udy AA, Baptista JP, Lim NL, et al (2014) Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med 42:520–7
49. Grundy SM (2004) Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89:2595–600
50. Harris DG, McCrone MP, Koo G, et al (2015) Epidemiology and outcomes of acute kidney injury in critically ill surgical patients. J Crit Care 30:102–6
51. Piccinni P, Cruz DN, Gramaticopolo S, et al (2011) Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT). Minerva Anestesiol 77:1072–83
52. Hites M, Taccone FS, Wolff F, et al (2013) Case-control study of drug monitoring of ß-lactams in obese critically ill patients. Antimicrob Agents Chemother 57:708–15
53. WHO expert consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157–63
54. Spellwin G. BMI for Men increases Health Insurances for Bodybuilders and Athletes. Available from http://bodybuilding.elitefitness. com/bmi-men-body-builder-athletes?s=7938c37dbc8b3fe89 8914db0aeee5605. [Accessed on October 24, 2014]
55. Green B, Duffull SB (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 58:119–3356.
56. Wurtz R, Itokazu G, Rodvold K (1997) Antimicrobial dosing in obese patients. Clin Infect Dis 25:112–8
57. Janson B, Thursky K (2012) Dosing of antibiotics in obesity. Curr Opin Infect Dis 25:634–49
58. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
59. Cirillo M, Anastasio P, De Santo NG (2005) Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant 20:1791–8
60. Verhave JC, Fesler P, Ribstein J, et al (2005) Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 46:233–41
61. Aggarwal N, Porter AC, Tang IY, et al (2012) Creatinine-based estimations of kidney function are unreliable in obese kidney donors. J Transplant 2012:872–94
62. Levey AS, Bosch JP, Lewis JB, et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–70
63. Salazar DR, Corcoran GB (1988) Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 84:1053–60
64. Demirovic JA, Pai AB, Pai MJ (2009) Estimation of creatinine clearance in morbidly obese patients. Am J Health-Syst Pharm 66:642–8
65. Levey AS, Stevens LA, Schmid CH, et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–12
66. Baptista JP, Udy AA, Sousa E, et al (2011) A comparison of estimates of glomerular filtration in critically ill patients. Crit Care 15:R139
67. Roberts JA, Norris R, Paterson DL, Martin JH (2011) Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 73:27–36
68. Taccone FS, Cotton F, Roisin S, et al (2012) Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 56:2129–31
69. Newman D, Scheetz MH, Adeyemi OA, et al (2007) Serum piperacillin/ tazobactam pharmacokinetics in a morbidly obese individual. Ann Pharmacother 41:1734–39
70. Deman H, Verhaegen J, Willems L, Spriet I (2012) Dosing of piperacillin/tazobactam in a morbidly obese patient. J Antimicrob Chemother 67:782–83
71. Roberts JA, Ulldemolins M, Roberts MS, et al (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332–9
72. Rich BS, Keel R, Ho VP, et al (2012) Cefepime dosing in the morbidly obese patient population. Obes Surg 22:465–71
73. Chen M, Nafziger AN, Drusano, et al (2006) Comparative pharmacokinetics and pharmacodynamic target attainment of Ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 50:1222–27
74. Cheatham SC, Fleming MR, Healy DP, et al (2014) Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit. J Clin Pharmacol 54:324–30
75. Roberts JA, Lipman J (2013) Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 41:489–95
76. Sturm A, Allen N, Rafferty KD, et al (2014) Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. Pharmacotherapy 34:28–35
77. Cheatham SC, Fleming MR, Healy DP, et al (2013) Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. Antimicrob agents 41:52–56
78. Zakrison TL, Hille DA, Namias N (2012) Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillintazobactam. Surg Infect 13:38–42
79. Buijk SE, Mouton JW, Gyssens IC, et al (2002) Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28:936–42
80. Pai MP, Nafziger AN, Bertino Jr SB (2011) Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob. Agents Chemother. 55:4006–11
81. Pai MP, Rodvold KA (2014) Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuck- Zaske dosing method revisited in the era of obesity. Diagnostic Microbiology and Infectious Diseases 78:178–87
82. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA (1983) Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 24:643–7
83. Ross AL, Tharp JL, Hobbs GR, et al (2013) Evaluation of extended interval dosing aminoglycosides in the morbidly obese population. Adv Pharmacol Sci 2013:194389
84. Wysocki M, Delatour F, Faurisson F, et al (2001) Continuous intermittent infusion of vancomycin in severe Staphylococcal infections: Prospective randomized study. Antimicrob Agents Chemother 45:2460–7
85. Cataldo MA, Tacconelli E, Grilli E, et al (2012) Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 67:17–24
86. Roberts JA, Taccone F, Udy AA, et al (2011) Vancomycin dosing in critically ill patients: robust methods for improved continuousinfusion regimens. Antimicrob Agents Chemother 55:2704–9
87. Blouin RA, Bauer RA, Miller DD, et al (1982) Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 21:575–80
88. Moffett BS, Kim S, Edwards MS (2011) Vancomycin dosing in obese pediatric patients. Clin Pediatr (Phila) 50:442–6
89. Grace E (2012) Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. Agents Antimicrob Chemoth 67:1305–10
90. Lodise TP, Lomaestro B, Graves J, Drusano GL (2008) Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 52:1330–36
91. Lodise TP, Patel N, Lomaestro BM, et al (2009) Relationship between initial Vancomycin concentration-time profile and nephrotoxicity among hospitalzed patients. CID 49:507–14
92. Van Hal SJ, Paterson DL, Lodise TP (2013) Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemotherap 57:734–44
93. Hanrahan TP, Harlow G, Hutchinson J, et al (2014) Vancomycinassociated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis. Crit Care Med 42:2527–36
94. Conil JM, Georges B, de Lussy A, et al (2008) Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Intl J Antimcrob Agents 32:505–10
95. Benko R, Matuz M, Doro P, et al (2007) Pharmacokinetics and pharmacodynamics of levofloxacin i critically ill patients with ventilator-associated pneumonia. Intl J Antimicrob Agents 30:162–8
96. Kees MG, Weber S, Kees F, Horbach T (2011) Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients 66:2330–5
97. Allard S, Kinzig M, Boivin G, et al (1993) Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 54:368–7398.
98. Utrup TR, Mueller EW, Healy DP, et al (2010) High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. Ann Pharmacother 44:1660–4
99. Cook AM, Martin C, Adams VR, Morehead RS (2011) Pharmacokinetics of intravenous levofloxacin administered at 750 milligrams in obese adults. Antimicrob Agents Chemother 55:3240–43
100. Luque S, Grau S, Valle M, et al (2011) Levofloxacin weightadjusted dosing and pharmacokinetic disposition in a morbidly obese patient. J Antimicrob Chemother 66:1653–4
101. Pai MP, Cojutti P, Pea F (2014) Levofloxacin dosing regimen in severely morbidly obese patients (BMI >40 kg/m2) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring. Clin Pharmacokinet 53:753–62
102. Mersfelder TL, Smith CL (2005) Linezolid pharmacokinetics in an obese patient. Am J Health Syst Pharm 53:464–7
103. Tsuji Y, Hiraki Y, Matsumoto K, et al (2012) Evaluation of pharmacokinetics in an old obese Japanese patient. Scand J Infect Dis 44:626–29
104. Stein GE, Schooley SL, Peloquin CA, et al (2005) Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 39:427–32
105. Bhalodi AA, Papasavas PK, Tishler DS, et al (2012) Pharmacokinetics of intravenous linezolid in moderately to morbidly obese adults. Antimicrob Agents Chemother 57:1144–49
106. Meagher AK, Forresr A, Rayner CR, et al (2003) Population pharmacokinetics of linezolid in patients treated in a compassionateuse program. Antimicrob Agents Chemother 47:548–53
107. Boselli E, Breilh D, Rimmele T, et al (2005) Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 33:1529–33
108. Buerger C, Plock N, Dehghanyar P, et al (2006) Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 50:2455–63
109. Beer R, Engelhardt KW, Pfausler B, et al (2007) Pharmacokinetics of linezolid in cerebral spinal fluid and plasma in neurointensive care patients with Staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 51:379–82
110. Michalopoulos AS, Falagas ME (2011) Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 1:30
111. Markou N, Markantonis SL, Dimitrakis E, et al (2008) Colistin serum concentrations after intravenous administration in patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Therapeutics 30:143–51
112. Plachouras D, Karvanen M, Friberg LE, et al (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistine after intravenous administration in critically ill patients with infections caused by gram-negative bacteria 53:3430–6
113. Garonzik SM, Li J, Thamlikitkul V, et al (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing strategies for various categories of patients. Antimicrob Agents Chemother 55:3284–94
114. Mohamed AF, Karaiskos I, Plachouras D, et al (2012) Application of a loading dose of colistin methanesulfate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:4241–9
115. Gauthier TP, Wolowich WR, Reddy A, et al (2012) Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 56:2392–6
116. Boisson M, Jacobs M, Grégoire N, et al (2014) Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 58:7331–9
117. Xie J, Wang T, Sun J, et al (2014) Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/ pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Intl J Infect Dis 18:62–7
118. Pai MP (2013) Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults. J Antimicrob Chemother 69:190–9
119. De Pascale G, Montini L, Pennisi M, et al (2014) High dose tigecycline in critically ill patients with severe infecions due to multidrug-resistant bacteria. Crit Care 18:R90
120. Safdar N, Andes D, Craig WA (2004) In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 48:63–8
121. Dvorchik B, Damphousse D (2005) The pharmacokinetics of daptomycin in moderately obese, morbidly obese and matched nonobese subjects. J Clin Pharmacol 45:48–56
122. Falcone M, Russo A, Venditti M, et al (2013) Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 57:1568–76
123. Pai MP, Norenberg JP, Anderson T, et al (2007) Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 51:2741–7